Repligen Corp
Could not find a ticker for this position, may be a filing error
A maker of tools and consumables for biologic drug manufacturing, Repligen supplies cell-retention filters, pre-packed columns, purification resins, and growth factors used by drugmakers worldwide. Founded in 1981 in Cambridge, Massachusetts, by two molecular biology professors, it focused entirely on bioprocessing starting in 2012. Its name blends "replication" and "genetics," a nod to its roots in recombinant protein science.
1.00% Convertible Senior Notes due December 15, 2028
Sold 451.8K
Sold 408.9K
Granted 10.0K
Granted 15.0K · Sold 15.0K
Granted 950.9K · Sold 505.0K
Granted 227.0K · Bought 5.0K · Sold 170.1K
Granted 189.1K · Bought 19.5K · Sold 114.7K
Granted 780.1K · Bought 2.0K · Sold 625.4K
Granted 213.7K · Sold 149.2K
Granted 49.7K · Bought 15.0K · Sold 5.0K
Granted 77.5K · Sold 16.3K
Granted 19.3K · Bought 21.0K
Granted 40.1K
Granted 142.8K · Sold 102.2K
Granted 213.4K · Sold 148.6K
Granted 6.8K · Sold 12.4K
Granted 40.0K · Sold 8.9K
Granted 16.4K · Bought 5.0K
Granted 82.3K · Sold 61.2K
Granted 22.2K · Sold 733
Granted 3.5K · Bought 4.9K
Granted 10.0K
Granted 10.0K
Granted 2.3K
Granted 4.2K · Bought 625
Granted 120.5K · Sold 115.0K
Granted 49.8K · Bought 1.2K · Sold 44.3K
Granted 5.0K
Granted 4.1K
Granted 3.9K
Granted 10.0K · Sold 10.0K
Granted 2.8K · Bought 250
Granted 14.5K · Sold 14.5K
Granted 23.3K · Bought 2.0K · Sold 23.3K
Granted 210.5K · Bought 12.0K · Sold 264.6K
Granted 44.0K · Sold 43.0K
Granted 40.0K · Sold 30.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +5 co-filersDirect Beneficial Owner · 4 transactions | — | 17.49Mas of Jul 2009 | — | — | 451.8K |
| Eddleman Roy T10% owner · 13 transactions | — | 8.41Mas of Aug 2018 | — | — | 408.9K |
| Schimmel PaulDirector · 3 transactions | — | 665.1Kas of Jun 2007 | 10.0K | — | — |
| Rich AlexanderDirector · 6 transactions | — | 436.5Kas of Sep 2008 | 15.0K | — | 15.0K |
| Herlihy Walter CPRESIDENT, CEO, Director · 59 transactions | — | 262.4Kas of May 2015 | 950.9K | — | 505.0K |
| Rusche James RSENIOR VICE PRESIDENT · 43 transactions | — | 95.8Kas of Dec 2016 | 227.0K | 5.0K | 170.1K |
| Dawes Karen ADirector · 118 transactions | — | 92.8K | 189.1K | 19.5K | 114.7K |
| Hunt AnthonyDirector · 198 transactions | — | 89.1K | 780.1K | 2.0K | 625.4K |
| Witt Daniel PSenior Vice President · 45 transactions | — | 73.1Kas of Jun 2014 | 213.7K | — | 149.2K |
| Cooper Glenn L MDDirector · 16 transactions | — | 64.7Kas of May 2019 | 49.7K | 15.0K | 5.0K |
| Loeillot OlivierChief Executive Officer, Director · 15 transactions | — | 54.2K | 77.5K | — | 16.3K |
| Goldberg Alfred LewisDirector · 5 transactions | — | 40.3Kas of May 2015 | 19.3K | 21.0K | — |
| Muir Glenn PDirector · 15 transactions | — | 40.1K | 40.1K | — | — |
| Snodgres JonChief Financial Officer · 85 transactions | — | 37.4Kas of May 2023 | 142.8K | — | 102.2K |
| Benjamin HowardVP Business Development · 34 transactions | — | 36.6Kas of Dec 2017 | 213.4K | — | 148.6K |
| Gebski ChristineSee Remarks · 25 transactions | — | 27.4Kas of May 2024 | 6.8K | — | 12.4K |
| Bylund JamesChief Operating Officer · 36 transactions | — | 25.4K | 40.0K | — | 8.9K |
| Henry Earl WebbDirector · 4 transactions | — | 21.4Kas of May 2013 | 16.4K | 5.0K | — |
| Kuriyel RalfSenior VP, R&D · 79 transactions | — | 20.1K | 82.3K | — | 61.2K |
| Garland Jason KCFO · 10 transactions | — | 19.4K | 22.2K | — | 733 |
| Madaus Martin DDirector · 12 transactions | — | 14.0K | 3.5K | 4.9K | — |
| Harris Timothy ScottVP Corporate Development · 1 transaction | — | 10.0Kas of Jan 2006 | 10.0K | — | — |
| Muehl Daniel WCFO · 1 transaction | — | 10.0Kas of Jan 2006 | 10.0K | — | — |
| Douglass Brian RobbCHIEF PRODUCT OFFICER · 3 transactions | — | 8.0K | 2.3K | — | — |
| Eglinton Manner CarrieDirector · 6 transactions | — | 5.5K | 4.2K | 625 | — |
| Kelly William JChief Accounting Officer · 19 transactions | — | 5.5Kas of Feb 2014 | 120.5K | — | 115.0K |
| Barthelemy NicolasDirector · 29 transactions | — | 5.4K | 49.8K | 1.2K | 44.3K |
| Mhatre RohinDirector · 6 transactions | — | 5.0K | 5.0K | — | — |
| Hughes ViolettaCHIEF ACCOUNTING OFFICER · 1 transaction | — | 4.1K | 4.1K | — | — |
| Konstantinov KonstantinDirector · 5 transactions | — | 3.9K | 3.9K | — | — |
| Whitehouse LauraVice President · 7 transactions | — | 3.5Kas of Mar 2006 | 10.0K | — | 10.0K |
| Pax MargaretDirector · 5 transactions | — | 3.0K | 2.8K | 250 | — |
| Day Barbara BurnimFormer Vice President · 8 transactions | — | 2.0Kas of Jan 2006 | 14.5K | — | 14.5K |
| Griffith Michael ADirector · 8 transactions | — | 1.9Kas of Nov 2014 | 23.3K | 2.0K | 23.3K |
| Ryan Thomas F JrDirector · 91 transactions | — | 1.5Kas of Mar 2022 | 210.5K | 12.0K | 264.6K |
| Cox JohnDirector · 18 transactions | — | 923as of Mar 2020 | 44.0K | — | 43.0K |
| Landy HalVice President · 3 transactions | — | 0as of Jun 2007 | 40.0K | — | 30.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.25M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.